These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35443252)

  • 1. PIM1 is a Poor Prognostic Factor for and Potential Therapeutic Target in Serous Carcinoma of the Endometrium.
    Takeuchi H; Miyamoto T; Fuseya C; Asaka R; Ida K; Ono M; Tanaka Y; Shinagawa M; Ando H; Asaka S; Shiozawa T
    Int J Gynecol Pathol; 2023 May; 42(3):282-292. PubMed ID: 35443252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis.
    Zhao B; Liu L; Mao J; Zhang Z; Wang Q; Li Q
    Cell Death Dis; 2018 Feb; 9(3):307. PubMed ID: 29472550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.
    Leung CO; Wong CC; Fan DN; Kai AK; Tung EK; Xu IM; Ng IO; Lo RC
    Oncotarget; 2015 May; 6(13):10880-92. PubMed ID: 25834102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway.
    Cao L; Wang F; Li S; Wang X; Huang D; Jiang R
    Cancer Lett; 2019 Mar; 444():116-126. PubMed ID: 30583073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
    Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
    Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression.
    Xiang X; Yuan D; Liu Y; Li J; Wen Q; Kong P; Gao L; Zhang C; Gao L; Peng X; Zhang X
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):800-806. PubMed ID: 30020405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAB3 upregulates PIM1 expression by directly activating the TAK1-STAT3 complex to promote colorectal cancer growth.
    Li Q; Chen L; Luo C; ChenYan ; Ge J; Zhu Z; Wang K; Yu X; Lei J; Liu T; Peng X; Liu X; Yuan R
    Exp Cell Res; 2020 Jun; 391(1):111975. PubMed ID: 32229191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological significance of PIM1 kinase in osteosarcoma.
    Liao Y; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
    J Orthop Res; 2016 Jul; 34(7):1185-94. PubMed ID: 26687194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.
    Zhang X; Su Q; Zhang Y; Rong R; Chen S; He L; Zhuang W; Li B
    Ann Hematol; 2024 Aug; 103(8):2905-2915. PubMed ID: 38424303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.
    Zippo A; De Robertis A; Serafini R; Oliviero S
    Nat Cell Biol; 2007 Aug; 9(8):932-44. PubMed ID: 17643117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
    Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
    Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion.
    Eerola SK; Santio NM; Rinne S; Kouvonen P; Corthals GL; Scaravilli M; Scala G; Serra A; Greco D; Ruusuvuori P; Latonen L; Rainio EM; Visakorpi T; Koskinen PJ
    Cell Commun Signal; 2019 Nov; 17(1):148. PubMed ID: 31730483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.
    Ha S; Iqbal NJ; Mita P; Ruoff R; Gerald WL; Lepor H; Taneja SS; Lee P; Melamed J; Garabedian MJ; Logan SK
    Oncogene; 2013 Aug; 32(34):3992-4000. PubMed ID: 22986532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.
    van der Meer R; Song HY; Park SH; Abdulkadir SA; Roh M
    Clin Cancer Res; 2014 Jun; 20(12):3211-21. PubMed ID: 24771642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells.
    Kim W; Youn H; Kwon T; Kang J; Kim E; Son B; Yang HJ; Jung Y; Youn B
    Pharmacol Res; 2013 Apr; 70(1):90-101. PubMed ID: 23352980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation.
    Gao X; Liu X; Lu Y; Wang Y; Cao W; Liu X; Hu H; Wang H
    Breast Cancer; 2019 Sep; 26(5):663-671. PubMed ID: 30989585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIM1: a promising target in patients with triple-negative breast cancer.
    Zhao W; Qiu R; Li P; Yang J
    Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.